In this method of imaging, radiolabeled technetium is injected into the body where it binds to cardiac amyloid deposits. A subsequent scan is taken to determine where the tracer stays, therefore highlighting the amyloid deposition in the heart. This method allows for a noninvasive definitive diagnosis of cardiac amyloidosis (as in the past an endomyocardial biopsy was required)

Mass spectrometry
Mass spectrometry can be used to determine whether the protein is light-chain or familial amyloidosis by identifying the protein subunit. Treatments
Treatments differ according to the type of amyloidosis present. The majority of treatment is aimed at preserving heart function and treating heart failure symptoms.Light chain (AL-CM) Treatment: Since the cause of this subtype of cardiac amyloidosis is the excessive production of free light chains, the major goal of treatment is the reduction in concentration of light chains. For light-chain amyloidosis, the use of FLC assays and NT-proBNP levels can be used to monitor the progression of amyloidosis and any response to treatments. One of the major routes to decrease the production of these excess light chains is to kill the abnormal cells that are producing them. Chemotherapeutic agents such as melphalan or bortezomib can be used to kill off the abnormal cell line that is producing the free light chains. Following chemotherapy, a bone marrow transplant can be utilized to restore the normal cell lines. There are newer medications (ixazomib, carfilzomib, daratumumab, elotuzumab) under research for the treatment of multiple myeloma that can help to decrease the production of free light chains.
Premature infants who have been given large amounts of benzyl alcohol (99–405 mg/kg/day) have experienced "gasping syndrome". Although enoxaparin is used to prevent blood clots, pregnancy alone can raise a womans risk of clotting. Side effects
Uncommon (<1%)

In people with unstable angina or non-Q-wave myocardial infarction:
Atrial fibrillation, heart failure, lung edema, pneumonia:  ≥ 0.5%vCommon (>1%)

Thrombocytopenia, i.e. can be associated with heparin-induced thrombocytopenia (0.5-5.0% of persons treated for at least five days)
Elevations in serum aminotransferases: 5.9%-6.1%
In people undergoing abdominal or colorectal surgery:
Bleeding, anemia, ecchymosis: ≥ 2%
In persons undergoing hip or knee replacement:
Fever, nausea, anemia, edema, peripheral edema: ≥ 2%
In persons with severely restricted mobility during acute illness:
Dyspnea, thrombocytopenia, confusion, diarrhea, nausea: ≥ 2%
In people being treated for deep vein thrombosis:
Injection site hemorrhage, injection site pain, hematuria: ≥ 2%Frequency under investigation

Local reactions: local irritation, pain, hematoma, ecchymosis, erythema
Bleeding
Hyperkalemia
Transaminitis
Hemorrhage

Boxed warning
The FDA issued a revision to the boxed warning for enoxaparin in October 2013. The revision recommends exercising caution regarding when spinal catheters are placed and removed in persons taking enoxaparin for spinal puncture or neuroaxial anesthesia. It may be necessary to delay anticoagulant dosing in these persons in order to decrease the risk for spinal or epidural hematomas, which can manifest as permanent or long-term paralysis. Persons at risk for hematomas may present with indwelling epidural catheters, concurrent use of medications that worsen bleeding states such as non-steroidal anti-inflammatory drugs (NSAIDs), or a past medical history of epidural or spinal punctures, spinal injury, or spinal deformations. The FDA recommends that at-risk persons be monitored for bleeding and neurological changes.